← Browse by Condition
Medical Condition

chemotherapy

Total Trials
16
Recruiting Now
16
Trial Phases
Phase 2, Phase 3, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for chemotherapy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — chemotherapy Clinical Trials

How many clinical trials are currently recruiting for chemotherapy?
ClinicalMetric currently tracks 16 actively recruiting clinical trials for chemotherapy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 16. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for chemotherapy?
chemotherapy research spans Phase 1 (2 trials), Phase 2 (8 trials), Phase 3 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a chemotherapy clinical trial?
Eligibility criteria for chemotherapy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
8
Phase 3
4
Top Sponsors
Ukrainian Society of Clinical Oncology 1 trial
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 1 trial
Dr. Chris Gaffney 1 trial
Shanghai Jiao Tong University School of Medicine 1 trial
Yonsei University 1 trial

Recruiting Clinical Trials

NCT06028737 Phase 2, Phase 3
Recruiting
Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Enrollment
150 pts
Location
Lithuania, Ukraine
Sponsor
Ukrainian Society of Clinical ...
View Trial →
NCT06429839 Phase 2
Recruiting
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
Enrollment
55 pts
Location
China
Sponsor
Cancer Institute and Hospital,...
View Trial →
NCT07341217
Recruiting
Chemo Brain Prehab Project
Enrollment
86 pts
Location
United Kingdom
Sponsor
Dr. Chris Gaffney
View Trial →
NCT05125055 Phase 2, Phase 3
Recruiting
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
Enrollment
80 pts
Location
China
Sponsor
Shanghai Jiao Tong University ...
View Trial →
NCT06595108
Recruiting
Atezolizumab and BEvacizumab With STereotactic Body Radiotherapy for Advanced Hepatocellular Carcinoma
Enrollment
33 pts
Location
South Korea
Sponsor
Yonsei University
View Trial →
NCT06896422 Phase 1
Recruiting
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
Enrollment
80 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT04453826 Phase 3
Recruiting
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
Enrollment
388 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT07443618
Recruiting
Measuring Fluid Buildup in Cancer Patients
Enrollment
46 pts
Location
Denmark
Sponsor
Jens Rikardt Andersen
View Trial →
NCT06308354
Recruiting
Colorectal Cancer Dataset in Xijing Hospital From 2011
Enrollment
40,000 pts
Location
China
Sponsor
Xijing Hospital
View Trial →
NCT07072351 Phase 1, Phase 2
Recruiting
Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma
Enrollment
88 pts
Location
China
Sponsor
West China Hospital
View Trial →
NCT07085182 Phase 2
Recruiting
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer:A Prospective, Single-Arm, Phase II Study
Enrollment
20 pts
Location
China
Sponsor
Zibo Municipal Hospital
View Trial →
NCT06492083
Recruiting
A Stuty on the Treatment and Nursing Care of CIPN Patients With Traditional Chinese Medicine Hot Package
Enrollment
90 pts
Location
China
Sponsor
The Fourth Affiliated Hospital...
View Trial →
NCT06758830 Phase 2, Phase 3
Recruiting
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Enrollment
400 pts
Location
Lithuania
Sponsor
National Cancer Center Affilia...
View Trial →
NCT07339488 Phase 2
Recruiting
Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
Enrollment
39 pts
Location
China
Sponsor
Chuangzhen Chen
View Trial →
NCT07742332 Phase 2
Recruiting
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
Enrollment
160 pts
Location
China
Sponsor
Peng Zhang
View Trial →
NCT04889924
Recruiting
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
Enrollment
820 pts
Location
Australia, Spain
Sponsor
Hospital Universitari de Bellv...
View Trial →

Related Conditions

radiotherapy (5) gastroesophageal junction adenocarcinoma (2) chemoradiotherapy (2) immunotherapy (2) hypofractionated radiotherapy (2) tislelizumab (2) radiotherapy side effect (2) gastric cancer (1) stomach cancer (1) gastroesophageal cancer (1) gastric adenocarcinoma (1) advanced gastric adenocarcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology